Table 1.
Demographic and clinical characteristics of participants at baseline
| Characteristics | Participants (n = 921) |
|---|---|
| Age, years | 28.9 ± 3.5 |
| Body mass index, kg/m2 | 21.8 ± 3.1 |
| Anti-Müllerian hormone, ng/mL | 12.3 ± 3.6 |
| Antral follicle count, n | 34.3 ± 18.3 |
| Follicle-stimulating hormonea, IU/mL | 8.5 ± 1.9 |
| Progesteronea, ng/mL | 0.7 ± 1.8 |
| Luteinizing hormonea, IU/L | 14.3 ± 6.9 |
| Free testosterone indexa | 5.2 ± 4.7 |
| Menstrual cycles, n (%) | |
| Amenorrhea | 52 (5.6) |
| Oligomenorrhea | 850 (92.3) |
| Regular | 19 (2.0) |
| Polycystic ovaries on ultrasound, n (%) | |
| Both ovaries | 777 (84.4) |
| One ovary | 144 (15.6) |
| Duration of infertility, years | 3.7 ± 2.6 |
| Type of infertility, n (%) | |
| Primary | 747 (81.1) |
| Secondary | 174 (18.9) |
| Number of IVF attempts, n, (%) | |
| 1 | 814 (88.4) |
| 2 | 80 (8.7) |
| 3 | 27 (2.9) |
| Indications for IVM, n (%) | |
| Tubal factors | 18 (2.0) |
| Male factors | 13 (1.4) |
| Ovulation induction failure | 862 (93.6) |
| Previous OHSS with COH | 18 (2.0) |
| Other | 10 (1.1) |
Values are mean ± standard deviation, or number of women (%)
COH, controlled ovarian hyperstimulation, IVF in vitro fertilization, IVM in vitro maturation, OHSS ovarian hyperstimulation syndrome
aHormone levels were assessed at the first physician visit, on the second day of progestogen-induced bleeding